Foghorn Therapeutics Inc. Common Stock

Day range

$1.93 – $2.06

Open

$1.99

Prev close

$2.00

Volume

382.29K

Market cap

$118.77M

Shares out

59.39M

P/E

—

P/S

3.23

P/B

-1.47

P/FCF

—

ROE

79.7%

ROA

-31.8%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Workforce reductionOct 1, 2026

  In connection with this decision, the Company announced a reduction in its workforce by approximately 40% of its current workforce. The Company expects to substantially complete the reduction in its workforce in the fourth quarter of 2026. Following the changes, the Company expects to have approximately 65 full-time employees.

• Investor presentationAug 6, 2026

  The Company is furnishing as Exhibit 99.2 to this Current Report on Form 8-K a presentation, dated August 2026, which the Company intends to use in meetings with or presentations to investors.

• Annual meeting resultsJun 24, 2026

  On June 24, 2026, Foghorn Therapeutics Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). The stockholders of the Company elected each of the following director nominees to serve until the 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal.

• Investor presentationMay 7, 2026

  The Company is furnishing as Exhibit 99.2 to this Current Report on Form 8-K a presentation, dated May 2026, which the Company intends to use in meetings with or presentations to investors.

• Investor presentationApr 21, 2026

  Foghorn Therapeutics Inc. (the "Company") is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a presentation, dated April 2026, which the Company intends to use in meetings with or presentations to investors.

Days to cover

4.3

Short interest

2.15M

Avg volume

504.88K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director
  neutralGlobeNewswire Inc.· Jul 1, 2026
• Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
  positiveGlobeNewswire Inc.· Apr 9, 2026
• Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
  positiveBenzinga· Jan 14, 2026
• Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
  positiveGlobeNewswire Inc.· Jan 9, 2026
• 4DMT Appoints Kristian Humer as Chief Financial Officer
  positiveGlobeNewswire Inc.· Nov 17, 2025